Дома и бани от новгородских мастеров без предоплаты
Дома и бани от новгородских мастеров без предоплаты
: The acquisition included GW’s cannabinoid product platform and clinical-stage programs for additional indications such as autism, schizophrenia, and multiple sclerosis-related spasticity.
While the GW Pharmaceuticals platform adds significant value, an investment in Jazz Pharmaceuticals carries its own risks. The company took on substantial debt to finance the $7.2 billion acquisition, leading to a temporary increase in leverage. Potential investors should monitor the company's progress in paying down this debt and the continued clinical trial success of its pipeline. buy stock in gw pharmaceuticals
Investment Rationale for GW Pharmaceuticals (via Jazz Pharmaceuticals) Potential investors should monitor the company's progress in
: Epidiolex was the first FDA-approved plant-derived cannabinoid medicine, used to treat severe forms of childhood-onset epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. It reached over $500 million in annual net sales in 2020 and has continued to expand globally as Epidyolex in Europe. buy stock in gw pharmaceuticals